Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

OBJECTIVE: To evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression. BACKGROUND: Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, has been approved for the preventive treatment of mi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Headache
Autors principals: Lipton, Richard B., Cohen, Joshua M., Galic, Maja, Seminerio, Michael J., Yeung, Paul P., Aycardi, Ernesto, Bigal, Marcelo E., Bibeau, Kristen, Buse, Dawn C.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Research Submissions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8251795/
https://ncbi.nlm.nih.gov/pubmed/33891348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.14097
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars